Literature DB >> 27012659

Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.

Tamara Strohm1, Burhan Chaudhry2, Mary A Willis2, Steven Shook2.   

Abstract

BACKGROUND: Reversible cerebral vasoconstriction syndrome (RCVS) has been associated with multiple medications, cocaine, pregnancy, migraine, and other conditions.
OBJECTIVES: RCVS associated with interferon beta use has never before been described.
METHODS: We describe the case of a 20-year-old female who developed acute onset severe headache and was found to have subarachnoid hemorrhage 2 months after initiating Rebif (Interferon beta-1a) for multiple sclerosis (MS). Cerebral angiography showed multiple areas of distal stenosis and dilatation with radiographic resolution 1 month later. RESULTS/
CONCLUSIONS: This is the first case report of RCVS in an MS patient treated with Rebif.
© The Author(s), 2016.

Entities:  

Keywords:  Beta-interferon; Rebif; multiple sclerosis; reversible cerebral vasoconstriction syndrome

Mesh:

Substances:

Year:  2016        PMID: 27012659     DOI: 10.1177/1352458516641774

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

Review 1.  An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.

Authors:  Caila Vaughn; Aisha Bushra; Channa Kolb; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

2.  Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.

Authors:  Vincenzo Dattola; Lilla Bonanno; Antonino Naro; Antonino Chillura; Anna Lisa Logiudice; Edoardo Sessa; Fausto Famà; Angelo Quartarone; Rocco Salvatore Calabrò; Silvia Marino; Margherita Russo
Journal:  Biomed Res Int       Date:  2017-09-13       Impact factor: 3.411

3.  Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients.

Authors:  Ilkka Rauma; Tiina Mustonen; Juha Matti Seppä; Maritta Ukkonen; Marianne Männikkö; Auli Verkkoniemi-Ahola; Marge Kartau; Jukka T Saarinen; Liisa Luostarinen; Sakari Simula; Mervi Ryytty; Riitta Ahmasalo; Jussi O T Sipilä; Ilkka Pieninkeroinen; Tero Tapiola; Anne M Remes; Hanna Kuusisto
Journal:  J Neurol       Date:  2021-07-13       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.